Cite this article as: Depypere LP, Daddi N, Gooseman MR, Batirel HF, Brunelli A, on behalf of the ESTS Learning Affairs Committee. The impact of coronavirus disease 2019 on the practice of thoracic oncology surgery: a survey of members of the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg 2020; doi:10.1093/ejcts/ezaa284.

The impact of coronavirus disease 2019 on the practice of thoracic oncology surgery: a survey of members of the European Society of Thoracic Surgeons (ESTS)

Lieven P. Depypere ^(b) ^{a,b,†}, Niccolò Daddi ^(b) ^{c,*†}, Michael R. Gooseman^d, Hasan F. Batirel ^(b) ^e and Alessandro Brunelli ^(b) ^d, on behalf of the ESTS Learning Affairs Committee

^a Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium

^b Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium

^c Department of Thoracic Surgery, Bologna University School of Medicine, Bologna, Italy

^d Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK

^e Department of Thoracic Surgery, Marmara University School of Medicine, Istanbul, Turkey

* Corresponding author. Thoracic Surgery Unit, Alma Mater Studiorum, Azienda Ospedaliero-Universitaria S.Orsola-Malpighi, Via Massarenti 9 - Pavilion 23, 40125 Bologna, Italy. Tel: +39-51-2144982; e-mail: niccolo.daddi@unibo.it (N. Daddi).

Received 30 April 2020; received in revised form 18 June 2020; accepted 27 June 2020



Abstract

OBJECTIVES: There is widespread acknowledgement that coronavirus disease 2019 (COVID-19) has disrupted surgical services. The European Society of Thoracic Surgeons (ESTS) sent out a survey to assess what impact the COVID-19 pandemic has had on the practice of thoracic oncology surgery.

[†]The first two authors contributed equally to this study.

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

METHODS: All ESTS members were invited (13-20 April 2020) to complete an online questionnaire of 26 questions, designed by the ESTS learning affairs committee.

RESULTS: The response rate was 23.0% and the completeness rate was 91.2%. The number of treated COVID-positive cases per hospital varied from fewer than 20 cases (30.6%) to more than 200 cases (22.7%) per hospital. Most hospitals (89.1%) postponed surgical procedures. All hospitals performed patient screening with a nasopharyngeal swab, but only 6.7% routinely tested health care workers. A total of 20% of respondents reported that multidisciplinary meetings were completely cancelled and 66%, that multidisciplinary decisions were not different from normal practice. Trends were recognized in prioritizing surgical patients based on age (younger than 70), type of surgery (lobectomy or less), size of tumour (T1-2) and lymph node involvement (N1). Sixty-three percent of respondents reported that surgeons were involved in daily care of COVID-19-positive patients. Fifty-three percent mentioned that full personal protective equipment was available to them when treating a COVID-19-positive patient.

CONCLUSIONS: The COVID-19 pandemic has created issues for the safety of health care workers, and surgeons have been forced to change their routine practice. However, there was no consensus about surgical priorities in lung cancer patients, demonstrating the need for the production of specific guidelines.

Keywords: (MEsH) Survey • Organization and administration • Thoracic surgery • Coronavirus disease 2019 • Pandemic

ABBREVIATIONS

COVID-19	Coronavirus disease 2019
CT	Computed tomography
ESTS	European Society of Thoracic Surgeons
PPE	Personal protective equipment
WHO	World Health Organization

INTRODUCTION

On 31 December 2019, the World Health Organization (WHO) was informed of a cluster of patients presenting with pneumonia in China. This disease, which was termed coronavirus disease 2019 (COVID-19) and was caused by the SARS-CoV-2 virus, spread worldwide, becoming a pandemic on 11 March 2020 [1]. Because COVID-19 has been found to be highly transmittable with a mortality of 0.3–15.06% [2], many countries have taken measures to limit the spread of the virus [3]. To deal with infected patients requiring mechanical ventilation, hospitals have created surge capacity with routine clinical practice severely disrupted [4]. Operating room personnel and equipment have been redeployed to critical care and COVID-19 wards. In some cases, operating rooms have been transformed into additional intensive care facilities [5].

The European Society of Thoracic Surgeons (ESTS) designed a questionnaire to assess how the COVID-19 pandemic has impacted the practice of thoracic oncology surgery by its members. The findings represent a snapshot of a specific period of the pandemic. They also reflect a specific situation during different phases of the pandemic [3]. The results of this survey will be disseminated to help thoracic surgeons appropriately manage their oncology practice during the COVID-19 pandemic.

MATERIALS AND METHODS

All ESTS members (1780 as of March 2020) received an e-mail informing them about the survey. They were invited to complete the questionnaire using a commercially available format (www.sur veymonkey.com) over 7 days from 13 April 2020 to 20 April 2020.

The survey was designed by the ESTS learning affairs committee and comprised 26 questions. Five questions assessed the background and specific practice of the surgeon and 21 questions assessed the impact of COVID-19 on his or her thoracic surgical practice. Three questions related to multidisciplinary meetings and treatment decisions; 3 questions, to patient screening; 2 questions, to preoperative assessment; 2 questions, to preoperative patient contact; 3 questions, to surgical planning; 2 questions, to protective equipment; 4 questions, to postoperative care and contact; and 2 questions, to the surgeon's personal situation. One final open-ended question explored thoughts about the future. The results of each question are presented in tables or bar charts, and the most important findings are presented in this manuscript. The other findings are presented in electronically available Supplementary Material, Tables S1 and S2.

RESULTS

Of 1780 surgeons, 409 (response rate 23%) submitted 373 complete responses (completeness rate 91%).

CONTEXT PART

Demographics and hospitals

Question 1: In which country do you practice? (Answer rate 383/ 409, 93.6%)

A total of 298 (77.8%) participants were from Europe, 39 (10.2%) from Asia, 20 (5.3%) from North America, 17 (4.5%) from South America, 8(2%) from Africa and 1 (0.2%) from Oceania (Fig. 1).

Question 2: In which type of institution do you practice? (Answer rate 405/409, 99%)

The majority of the respondents worked in academic hospitals (Supplementary Material, Fig. S1) (n = 290, 71.6%). Supraregional (non-academic) and regional (nonacademic) hospitals were 11.6% (n = 47) and 12.59% (n = 51), respectively.

Question 3: How many COVID-19 positive patients is your hospital treating? (Answer rate 405/409, 99%)



Figure 1: Impact of coronavirus disease 2019 (COVID-19) worldwide and the European Society of Thoracic Surgeons (ESTS) survey response. (A) World Health Organization (WHO) map describes the countries, areas or territories with COVID-19 cases reported during the 7 days from 14 April 2020 to 20 April 2020 [reproduced from https://covid19.who.int/ at WHO Coronavirus Disease (COVID-19) Dashboard; WHO permission ref 349467/2020]. (B) Countries in lockdown due to COVID-19 during the same period described in the WHO map. (C and D) All countries, areas or territories participating in the COVID-19 survey and their relative contributions.

The majority of respondents worked in hospitals treating no more than 20 patients with COVID-19 (30.6%). Conversely, 22.7% reported that their hospital was treating more than 200 infected patients (Supplementary Material, Fig. S2).

Question 4: How is the COVID-19 pandemic affecting normal functioning of your hospital? (Answer rate 405/409, 99%)

Most of the respondents answered that the functioning of the hospital was considerably (55.3%) or extremely (16.3%) affected (Supplementary Material, Fig. S3).

Question 5: Are the health care personnel tested in your hospital? (Answer rate 405/409, 99%)

Only 50% of health care workers were tested at their hospitals when symptomatic and 11% were not tested at all; 32% of respondents reported that workers were tested after being in contact with COVID-positive patients.

IMPACT OF CORONAVIRUS DISEASE 2019 PANDEMIC ON THORACIC SURGERY PATIENT CARE

Results are presented in Fig. 2.

Multidisciplinary tumour board

Question 6: How are multidisciplinary tumour meetings organized today? (Answer rate 405/409, 99%) A total of 48.9% of respondents were using web-based platforms. Interestingly, when answers were stratified by the number of treated COVID-19 positive patients per hospital, no differences were seen in distribution (Fig. 3A).

Question 7: Are multidisciplinary decisions influenced by the COVID-19 pandemic situation? (Answer rate 400/409, 97.7%)

The majority of respondents (66%) answered that treatment decisions were not influenced by COVID-19, but multidisciplinary decisions were clearly more influenced by the situation in hospitals treating more than 100 patients with COVID-19 (Fig. 3B).

Question 8: Given the current COVID-19 crisis please select which of the following hypothetical patients you would prioritize for surgery? (Answer rate 401/409, 98%)

We provided 5 case scenarios to be triaged (Fig. 4). The majority prioritized fit and younger patients with a cancer at risk of progression. Surgical management of slowly growing and smaller cancers, especially in older patients, tended to be deferred.

Coronavirus disease 2019 screening

Question 9: What thoracic surgical patients are being screened for COVID-19 in your department? (Answer rate 405/409, 99%) (Fig. 2)

The answers were variable with the same proportion of respondents reporting screening for all patients (25%), in-patients only (24%) or symptomatic patients only (23%).

Question 10: How are thoracic surgical patients screened for COVID-19 in your department? (Answer rate 400/409, 97.7%) (Fig. 2)

The majority (54%) responded that a nasopharyngeal swab alone was used for screening; 30% used a combination of swab and computed tomography (CT) chest imaging.

Question 11: Does the result of a COVID-19 positive test influence the surgical treatment of your patient? (Answer rate 398/ 409, 97.3%) (Fig. 2)

A total of 7% of respondents would proceed to surgery regardless of a positive test result. The majority stated a positive test result would be an indication to postpone surgery by 2 weeks in all patients (59%) or those with symptoms (19%).

Preoperative workup

Question 12: How is the preoperative oncological workup influenced by the COVID-19 pandemic situation? (Answer rate 400/ 409, 97.7%) (Fig. 2)

A total of 45% of participants answered that all examinations were available as usual. However, 56% reported that endobronchial or other examinations were delayed or unavailable. CTguided biopsies were less frequently available in more severely affected hospitals (Fig. 5A).

Question 13: Which of the following preoperative functional tests are not available due to the COVID-19 pandemic situation? (Answer rate 394/409, 96.3%) (Fig. 2)

Although all tests were available as normal for most participants (64%), the diffusing capacity for carbon monoxide and cardiopulmonary exercise tests were not available in more than 20% of cases.

When answers were stratified by the number per hospital of treated patients whose test results were positive for COVID-19, investigations were clearly more delayed or unavailable in hospitals treating more than 100 patients with COVID-19 (Fig. 5B).

Outpatient clinic: preoperative

Question 14: How is your preoperative contact with the patient influenced by the COVID-19 pandemic situation? (Answer rate 398/409, 97.3%) (Fig. 2)

Preoperative meetings with patients were still conducted face to face for 54% of respondents; 47% used telephone or video consultations when possible.

Question 15: Do you talk about COVID-19 with your patients preoperatively? (Answer rate 395/409, 96.5%) (Fig. 2)

Most respondents discussed with their patients the higher risk of surgery in the context of COVID-19 infection. However, 15% reassured their patients not to worry and 8.6% did not discuss COVID-19 infection preoperatively.

Planning

Question 16: How is your surgical planning affected by the COVID-19 pandemic situation? (Answer rate 400/409, 97.7%) (Fig. 2)

Almost half of the participants (47.5%) answered that only medically or oncologically urgent operations were performed due to shortage of staff and intensive care unit beds. In hospitals treating more patients who were positive for COVID-19, surgical planning was clearly more affected (Fig. 6A).

Question 17: How do you feel about the affected planning? (Answer rate 397/409, 97%) (Fig. 2)

stion 6	MULTIDISCIPLINARY (TUMOUR) BOARD		Nur
	How are multidisciplinary (turnar) meetings organized today? business as usual, but with hygienic measures (og social distancing)	RESPONS 21.48%	SES par 87
	less frequent meeting, but still in direct contact, with hygienic measures digital meeting using an e-platform, but with the same frequency	9.63%	39
	agolal meeting song an e-partnern, our less mequent. there are no scheduled meetings anymore (discussion at hoc)	20,00%	52 81
ition 7	Are multifluiplinary decisions influenced by the COMO-19 pandemic situation? not at all	11.75%	47
	no, not the treatment decision itself, but a degree of treatment urgency is mentioned yes, in locally advanced stages (IIIa) patients are more scheduled for systemic therapy	54.50% 15.25%	218 61
	yes, in locally advanced stages patients are less scheduled for systemic therapy and more for radiotherapy therapy yes, in locally advanced stages patients are less scheduled for systemic therapy and more for surgery	4.50%	18 17
	yes, in early stages patients scheduled for locoregional therapy get more radiation therapy and less surgery as a radiants scheduled for locoregional therapy get more radiation therapy and less surgery	8.25%	33
	yes, patients scheduled for locaregional therapy get less reduction therapy and more surgery	1.50%	6
illion 8	Orien the current CDVID-19 crisis presis presis belock which of the following hypothetical patients you would prioritise for surgery/ CASE 1 80 year old patient with slowly growing partly solid TLaND peripheral lung cancer	n (SEE FIGU
	CASE 2 65 year old patients with normal pulmonary function and no comorbidities with 3 cm RUL cancer		
	CASE 3 75 year old patient with compromised pulmonary function, PS 1, central cancer candidate to right pneumonectomy CASE 4 70 year old patient with single station N2 disease and right upper lobe cancer		
	CASE 5 55 year old patient with normal pulmonary function tests, N1 disease, cancer in the right lower lobe		
tion 2	COVID-19 SCR2231935 Million Advanced on standard and Anton summand the COVID-10 in our of descentement?		
DON ¥	what therease surgices patients are being screened par convolution your departmenter Only symptomatic patients in the emergency department. All emotypenalistic askedne (convictor and neurostation)	12.50%	50
	An sproveness, parents indexents, and valuations) Symptomatic patients and certain inpatient contacts depending on underlying pathology Allowatiers contacts colu	15.75%	63 66
	All patients (inpatient and outpatient)	24.50%	58
tion 10 pie	Now are thorack surgical patients screened for COVID-28 in your department? nasopharyptal seals	90.77%	364
HETS.	chint CT blood text for antibodies	37.41% 9.23%	150 37
	Spetum Bronchoaheolar lavage	3.49% 3.99%	14 16
	Other	4,74%	19
tion 11	Daes the result of a test influence the surgical treatment of your patient? no, in all cases, we will operate, but taking necessary procuritions and protection equipment when needed	7.04%	28
	yes, a COVID-19 positive elective patient with symptoms will not be operated on for 14 days and will be rescheduled afterwards	19.35%	77
	yes, every complicity possive decore parent with symptoms will not be operated on anymore and other therapy options will be suggested.	6.03%	24
	yes, every COVID-19 positive elective patient (with or without symptoms) will not be operated on nymore and other therapy options will be suggested, yes, even in COVID-19 positive unpart cases, we will try to find a non-surgical solution.	3.77%	15 18
	FREOPERATIVE WORKUP		
tion 12	How is the presperative oncological workup influenced by the COVID-38 pandemic situation? Not at all, all investigations are available in a normal time frame	44.75%	175
	only PET-CT Investigations are delayed, or unavailable only endobronchial investigations (bronchascops, EBUS) are delayed or unavailable	4.50%	18 122
	PET-CT and endobronchial investigations (bronchascopy, EBUS) are delayed or unavailable CT guided biopsy is not routinely available	14.50% 5.75%	58 23
tion 13	Which of the following preoperative functional tests are not available due to the COVID-19 pandemic situation?		
	All investigations are available as normal Spirometry with or without arterial blood gas analyses	63.45% 21.57%	250 85
	Diffusing capacity of Lung for Carbon Monoxide (DLCO) cardiac trebs ((CCG, Echocardiogram, stress test)	20.56% 3.30%	81 13
	Cardiopulmonary exercise test (OPET) V/Q scan	21.83% 30.66%	86 42
	OUTPATIENT CLINIC: PREOP		
tion 14	How is your presperative contact with the patient influenced by the COVID-19 pondemic situation? Business as usual, but with hygieric measures (og social distancing, surgical mask for surgeon and/or patient)	53.77%	214
	I try to avoid direct contact with patients and I have as much tele- or video contacts as possible All preoperative patient contacts are through tele- or video calls	41.21% 5.03%	164
tion 15	Do you talk about COVID-28 with your patients preoperatively?		
	No, this has nothing to do with their disease Yes, I don't want to, but patients ask about potential higher risks, and I tell them not to worry	8.61% 15.44%	34 61
	Yes, I don't want to, but patients ask about potential higher risks, and I tell them morbidity and mortality is higher Yes, I don't want to, but patients ask about potential higher risks, and I tell them we don't know that yet.	47.59% 28.35%	188
	PLANNING		
tion 16	How is your surgical placening offected by the COVID-19 pandemic situation? not at all: business as usual	2.50%	10
	slightly reduced capacity: some elective benign surgeries have been postponed, but no effect on inpatient care or ICU beds moderataly: more surgeries have been postponed, less staff and ICU beds available	17.50% 24.50%	70 56
	considerably: only medically or oncologically ungent surgeries are executed, minimal staff and KUI beds available estimates only encourses surgeries are executed, otherwise so staff and no KUI beds.	47.52%	190
tion 17	How do you feel about the offected skarning?		
	I agree with the current situation, this is what needs to be done I think we could even reduce thoracic surgery capacity for some time when needed	55.67% 16.37%	221 65
	I do not agree because my patients need more care than I can offer them, but I am forced because of lack of resources (protective material, ICU beds,-)	8.56%	34
	I do not agree because my patients need more care than I can offer them, but I am forced because of lack of staff (anesthetists, OR numae,) I do not agree because my patients need more care than I can offer them, but I am forced because of lack of staff (anesthetists, OR numae,)	6.55%	26
	resourses (protective matrial, KU beds,)	12,85%	51
tion 18	Are you and/or your thoracic surgery colleagues involved in the daily care of COVID-19 positive patients? No, some of us is taking care of them	17.145	
	Yes, some of us, but only surgical patients Yes, only patients from our department	97,9976	145
	Yes, special COVID shifts for other departments (e.e. ICU, IMC, emergency department)	25.31%	145 101 30
		25.31% 7.52% 29.82%	145 101 30 115
tion 19	EU1013.cd What kind of personal protective equipment (PPE) measures are taken during a COVID-19 negative thoracic surgical procedure?	25.31% 7.52% 29.82%	145 101 30 115
tion 19	5012577 What kind of personal protective equipment (PPR) measures are taken during a COVID-19 sepative throad: surgical procedure? Sandard CM equipment only for A suff The Take's dyoods for a tak's the tree con	25.31% 7.52% 29.82% 40.85% 13.28%	145 101 30 115 165 53
tion 19	SUGDT/# SUGDT/# SUGDT/# Sugdt // Second approach or equipment (PM) inseasing an antibient during a COVID-19 angotive thematic surgeout precedure? Total approach out it off in the file Total approach out it off in the file Total approach out it off interval	40.85% 17.54% 40.85% 13.28% 17.54%	165 101 30 115 53 70
tion 19	SUIDETER Section 2017 - 2017	40.85% 13.28% 17.54% 13.28% 17.54% 8.77% 15.04% 4.5 ^{1%}	165 101 30 115 53 70 35 60 10
tion 19	SUICETY Hand and of generated particular appointed (PPE) messares are taken during a COVID-19 angetable throwsic surgical procedure? standard CH expansion on the Visit and in the monon THP made, above, more and bace sheed for an estimation of PF22 made, and angetable throwsice surgical team THP made, above, more and bace sheed for an estimation of angetable standard angetable standard angetable THP made, above, more and bace sheed for an estimation of angetable standard angetable standard angetable THP made, above, more and bace sheed for an estimation of the standard angetable standard angetable standard angetable THP made, above, more and bace sheed for an estimation of the standard angetable standard and angetable standard angetable and angetable standard angetable standa	40.85% 13.28% 17.54% 8.77% 15.04% 4.51%	145 101 300 115 53 70 35 60 18
tion 19 tion 20	BUILDTP B	25.31% 25.31% 7.52% 29.32% 40.35% 13.28% 17.54% 8.77% 15.04% 4.51% 1.52% 7.34~	145 101 100 115 53 50 50 18 60 18
tion 19 tion 20	SUGGTY Suggest and a second protective resource (PVP) Inseasor are taken daring a COVID-19 angotive theoretic surgical procedure? The control global second and and in the room The control global second and and into the room The control global second and and into the room The control global second and and the room Suggest and a second and and and and and and and and and a	40.85% 25.31% 7.52% 29.82% 40.85% 13.28% 17.54% 8.77% 15.04% 4.51%	145 101 300 115 53 70 35 60 18 6 29 64
tion 19 tion 20	SUBSTATE	25.33% 7.52% 29.82% 40.85% 13.28% 13.28% 13.28% 15.04% 4.51% 15.04% 15.24% 7.34% 16.20% 15.24% 7.34% 15.22% 29.82%	145 100 300 115 53 53 70 35 60 18 6 29 6 6 51 211
tion 19 tion 20	SUICITY What should gramsses generative equipment (PMP) messame are taken adming at COVID-19 angother theoratic surgical procedure? aterdaed COI requirement any for all suffice THE Taked, galaxies, gaves and force should for interthetic drip and FFF2 much, a galaxies for the sergical taxen THE? Taked, galaxies, gaves and force should for interthetic drip and (FFF2 much, a galaxies for the sergical taxen THE? Taked, galaxies, gaves and force should for interthetic drip and (FFF2 much, a galaxies for the sergical taxen THE? Taked, galaxies, gaves and force should for interthetic drip and (FFF2 much, a galaxies for the sergical taxen COI ter planes spectrated equipment (PMP) messames are taken dring at COIDE-19 parative thermotic nargical personner? Taked, add on or copymonic drip for all suffice The taxet of the sergical taxes THE? Taked, galaxies, gaves and force should for inserthetic ordy and (FFF2 much, a galaxies for the sergical taxen THE? Taked, galaxies, gaves and force should for inserthetic ordy and (FFF2 much, a galaxies for the sergical taxen THE? Taked, galaxies, gaves and force should for inserthetic ordy and (FFF2 much, a galaxies for the sergical taxen THE? Taked, galaxies, gaves and force should for inserthetic ordy and (FFF2 much, a galaxies for the sergical taxen THE? Taked, galaxies, gaves and force should for inserthetic ordy and (FFF2 much, a galaxies for the sergical taxen THE? Taked, galaxies, gaves and force should for inserthetic ordy and (FFF2 much, a galaxies for the sergical taxen THE? Taked, galaxies, gaves and force should for inserthetic ordy and (FFF2 much, a galaxies for the sergical taxen THE? Taked, galaxies, gaves and force should for inserthetic ordy and (FFF2 much, a galaxies for the sergical taxen THE? Taked, galaxies, gaves and force should for inserthetic and saget formation when animous are sergered (ing, sizees instead; angemend [ing, sizees inserthetic and saget formation when animous are	25.33% 25.33% 7.52% 29.82% 40.85% 13.28% 13.28% 15.24% 4.51% 15.26% 7.34% 16.20% 16.20% 22.93% 53.42% 8.61%	146 100 30 111 53 53 70 35 60 38 60 38 60 38 60 38 60 38 61 29 64 51 211 34
tion 19 tion 20	DUDLING D	25.33% 7.52% 29.82% 40.83% 13.28% 17.54% 4.51% 15.04% 4.51% 1.52% 7.34% 16.20% 15.22% 53.42% 8.61%	146 100 30 111 53 53 70 35 60 18 6 29 64 51 21 21 21 24
tion 19 tion 20 tion 21	DUGTY Model and of personnel protochurd relevances (JPV) Inseasors or taken damp a COVD-13 angeste biosocia surgical person-bare? Model and of personnel protochurd relevances (JPV) Inseasors or taken damp a COVD-13 angeste biosocia surgical person-bare? Model and angeste surgical and the transmoster of the surgical taken Model and angester of the surgical damp and the surgers (JPV) angester or taken damp a COVD-13 angester biosocia surgers (JPV) Model and angester of the surgers (JPV) angester or taken damp a COVD-13 person-biosocia surgers (JPV) Model and angester of the surgers (JPV) angester or taken damp a COVD-13 person-biosocia surgers (JPV) Model and angester of the surgers (JPV) angester or taken damp a COVD-13 person-biosocia surgers (JPV) Model and angester of the surgers (JPV) angester or taken damp a COVD-13 person-biosocia surgers (JPV) Model and angester of the surgers (JPV) Model ange	25.33% 7.52% 29.32% 40.85% 13.28% 13.28% 13.28% 13.28% 15.2% 7.34% 15.2% 7.34% 16.20% 16.20% 16.20% 22.92% 53.42% 8.62%	146 100 300 115 53 70 35 53 70 35 60 18 53 18 6 53 18 54 51 11 34 55 55 55 70 35 55 55 70 35 55 55 70 35 55 70 35 55 70 35 55 70 35 55 70 35 55 70 35 55 70 35 55 70 35 55 70 35 55 70 35 55 70 35 55 70 35 55 70 35 55 70 35 70 5 70
tion 19 tion 20	SUGDY Most Also of gransser justice the equivalence (JPM) measure are taken during a COVID-19 angotake theoretic surgical preventive? The set of the se	25.33% 7.52% 29.32% 40.85% 13.28% 13.28% 13.28% 13.28% 13.28% 13.28% 15.2% 7.34% 15.2% 7.34% 15.2% 53.42% 53.42% 53.42% 53.42% 53.42%	146 100 30 30 111 50 50 35 60 18 60 18 62 99 64 51 121 111 34 156 51 21 21 21 21 21 21 21 21 21 21 21 21 21
tion 29 tion 20 tion 21	BURCH B	25.33% 7.52% 29.32% 40.85% 13.28% 13.28% 13.28% 13.28% 13.28% 13.28% 13.28% 13.28% 13.28%	1464 1001 300 301 115 53 30 700 35 50 80 81 8 8 9 9 64 51 34 34 132 56 50 50
tion 29 tion 20 tion 21	DUCATION	25.33% 7.52% 29.82% 40.85% 13.28% 17.54% 45.15% 15.04% 45.15% 15.26% 15.26% 15.26% 15.26% 15.28% 14.85% 36.07% 13.28%	1464 51 1001 1001 1001 1001 1001 1001 1001 10
tion 29 tion 20 tion 21	DUCTOR How a decide of personnal personnal wave and the second	25 31% 25 31% 40.83% 13.28% 13.28% 15.24% 15.25%	146464 1001 100
tion 19 tion 20 tion 21	DUGTOP How show a parsent parsent presenter (DPR) messame are taken daring a COVID-19 angotate howsic surgical presentare? The control of the standard of the second of th	40.35% 40.85% 40.85% 13.28% 40.85% 13.28% 40.85% 40.85% 13.28% 40.85% 15.27% 8.61% 15.28% 8.61% 15.29% 8.61% 13.28% 8.61% 13.28% 15.29% 15.22% 15	146464 1001 300 315 53 53 700 35 60 318 66 99 64 65 11 2111 34 34 135 56 65 135 50 50 50 2222 177 17 14 15 59 9
tion 19 tion 20 tion 21	BURCH B	23.52% 25.52% 40.85% 13.28% 15.52% 4.52% 13.75% 15.55% 4.52% 15.55% 5.54% 5.54% 5.54% 5.54% 5.54% 5.54% 8.61% 13.28% 8.61% 13.28%	146464 1001 101 101 101 101 101 101 1
tion 19 tion 20 tion 21 tion 22	BURCH THE ADDRESS OF ADDRESS	40 35% 5 29 32% 40 35% 13 28% 13 28% 5 29 32% 40 35% 13 28% 13 28% 13 28% 15 28% 16 28% 15 28%15 28% 15 28% 15 28% 15 28%15 28% 15 28%15 28% 15 28%15 28% 15 28%15 28% 15 28%15 28% 15 28% 15 28%15 28%15 28% 15 28%15 28% 15 28%15 28%15 28% 15 28%15 28%15 28% 15 28%15 28% 15 28%15 28% 15 28%15 28% 15 28%15 28% 15 28%15 28%15 28% 15 28%15 28%15 28% 15 28%15 28%16% 15 28%1	146464 1001 101 101 101 101 101 101 1
tion 19 tion 20 tion 21 tion 22	DUCLING How a construction of the sequence of the seq	40 35% 5 29 82% 40 35% 13 29% 13 29% 13 29% 15 29% 15 29% 15 29% 15 29% 15 29% 15 29% 15 29% 15 29% 15 29% 13 29% 14 25% 15 29% 15 29%15 20% 15 29% 15 29% 15 29% 15 29% 15 29%15 29% 15 29% 15 29%15 29% 15 29% 15 29%15 29%	1464 1001
tion 28 tion 20 tion 21 tion 22	BURCH Del Ad af generation de la construction (DPA) Researce are tables daving at CROID-13 Angeline theoratic anging prevenders? Researce Space Space Start Ber for the resource (DPA) Researce are tables daving at CROID-13 Angeline theoratic anging prevenders? REP 2014a, digates, gover and face shells for another (DPA) researce are tables daving at cognered lip, deren blackstram, tracterial wargers] REP 2014a, digates, gover and face shells for another resource and starts are spaced lip, deren blackstram, tracterial wargers] REP 2014a, digates, gover and face shells for another resource and starts are spaced lip, deren blackstram, tracterial wargers] REP 2014a, digates, gover and face shells for another resource and res	2 533% 2 535% 2 52% 2 52% 2 52% 2 52% 2 52% 2 52% 2 52% 2 52% 5 52	1464 1001
tion 19 tion 20 tion 21 tion 21	Build and any depresentation requirement (PPP) Researce are taken daring at CODA 39 angeline theoratic sampling prevention? TPP 2 reads, datasets of a daries the resource of the sample of the samp	25.31% 25.32% 25.32% 25.32% 25.32% 27.32% 13.32% 13.32% 13.32% 15.32%15.32% 15.32% 15.32%15.32% 15.32% 15.32%15.32% 15.32% 15.32%15.32% 15.32% 15.32%15.32% 15.32% 15.32%15.32% 15.32% 15.32%15.32% 15.32% 15.32%15.32%15.32% 15.32%15.32%15.32% 15	1464 1001 300 553 700 355 560 511 2011 34 551 550 550 550 550 520 202 202 202 202 202
tion 39 tion 20 tion 21 tion 22 tion 23		2533% 2533% 2532%2532% 2532%	14664 1001 100 1001 101 101 101 101
tion 39 tion 20 tion 21 tion 22 tion 23	DUCLATION	2533% 2533% 2532% 2532% 2532% 2532% 2532% 2532% 2532% 2532% 25342%25342% 25342% 25342%25342% 25342% 25342%25342% 25342% 25342%25342% 25342% 25342%25342% 25342% 25342%25342% 25342% 25342%25342% 25342% 25342%25342% 25342% 25342% 25342%25342% 25342% 25342% 25342%25342% 25342% 25342%25342% 25342% 25342%25342% 25342% 25342%25342% 25342% 25342%25342% 25342% 25342%25342% 25342% 25342%25342% 25342%25342% 25342% 25342%25342% 25342%25342% 25342% 25342%25342% 25342%25342% 25342%25342% 25342%25342% 25342%25342% 25342%25342% 25342%25342% 25342%25342% 25342%25346% 25342%25346% 25342%25346% 25346%25346%25346% 25346%25346%25346% 25346%25346%25346% 25346%25346%25346% 25346%25346%25346% 25346%25346%25346% 25346%25346%25346%2536% 25346%2536%2536% 25346%2536% 25346%2536%2536% 25346%2536% 2536%2536% 2536%2536% 2536%2536% 2536%2536% 2536%2536%2536% 2536%2536% 2536%2536%2536% 2536%2536% 2536%2536%2536% 2536%2536%2536% 2536%256% 2536%256% 2536%256% 2536%256% 2536%256% 2536%256% 2536%256% 2536%256% 2536%256% 2536%256% 2536%256% 2536%256% 2536%256% 2536%256% 256%256% 256%256% 256%256% 256% 256%256%256% 256% 256%26% 256%256% 256%26% 25	14640 1001 1001 1011
tion 29 tion 20 tion 21 tion 22	Build and and generating electrical sequences (CPUE) Researce are taken daring at CPUE) 34 angeines theoretic anging percendence? High 2 reach - globes to the daring the first first first reaching at CPUE 34 angeines theoretic angeing percendence? High 2 reach - globes to the daring the reaching of the sequences of the seque	25.31% 25.32% 25.32% 25.32% 25.32% 27.52% 25.32% 27.52% 27.52% 27.52% 27.52% 25.32% 25.34\% 25.34\%25.34\% 25.34\% 25.34\%25.34\% 25.34\%25.34\% 25.34\%25.34\% 25.34\%25.34\% 25.34\%25.34\% 25.34\%25.34\%25.34\% 25.34\%25.34\%25.34\%25.34\% 25.34\%26.34\%26.34\%27.34\% 27.34\%26.34\%27.34\% 27.34\%27	1464 1001 1001 1011
tion 29 tion 20 tion 21 tion 22 tion 23 tion 23	Build and any depresentation reaction reaction and any set of the second of the secon	2 533% 2 53% 2 52% 2 52%	146467 14010 14010 14010 14010 14010 14010 153 153 153 153 153 153 153 153
tion 19 tion 20 tion 20 tion 21 tion 22 tion 22		2533% 2535% 2532%	10000000000000000000000000000000000000
tion 19 tion 20 tion 21 tion 22 tion 23 tion 23 tion 24	Build and and expression of the sequence (1999) Reasons are taken daring at CODA 33 angeine theoratic anging prevention? Reading data and the sequence (1999) Reasons are taken daring at CODA 33 angeine theoratic angeing prevention? Reading data and the set of the tensors Reading data and the tensors Reading data and the set of the tensors Reading data and the tens	2 2 3 3 % 2 3 3 % 2 9 2 % 2 9 2 % 3 2 9 2 % 3 2 9 2 % 3 2 9 % 3 9 %	10000000000000000000000000000000000000
tion 19 tion 20 tion 21 tion 22 tion 23 tion 23 tion 23 tion 24	Build and and generative devices the analysis of the second of the seco	223378 23257 23275	1001 1001
tion 19 tion 20 tion 21 tion 21 tion 23 tion 23 tion 24 tion 25		2533% 2533% 2525% 255% 25% 2	1001 1001

Figure 2: Questionnaire results on the impact of coronavirus disease 2019 on thoracic surgical practice (questions 6–26).





Are multidisciplinary decisions influenced by the COVID-19 pandemic situation?

в



Figure 3: Multidisciplinary tumour boards. (A) Organization of multidisciplinary tumour boards stratified by impact per hospital. (B) Influence of the COVID-19 pandemic situation on multidisciplinary decisions stratified by impact per hospital. COVID-19: coronavirus disease 2019.

5



A Preferences of Thoracic Surgeons for Surgical Intervention in Different Patient Scenarios

55-year-old patient with normal pulmonary function tests, N1 disease, cancer in the right lower lobe

65-year-old patient with normal pulmonary function and no comorbidities with 3-cm RUL cancer

F75-year-old patient with normal pulmonary function, PS 1, central cancer candidate for right pneumonectomy

70-year-old patient with single station N2 disease and right upper lobe cancer

⁸⁰⁻year-old patient with slowly growing partly solid T1aN0 peripheral lung cancer

в		RANKING ORDER PICKED						
RANK		1	2	3	4	5	TOTAL RESPONSES	SCORE
1*	55-year-old patient with normal pulmonary function tests, N1 disease, cancer in the right lower lobe	45.00% 180	28.50% 114	16.25% 65	5.00% 20	5.25% 21	400	4.03
2*	65-year-old patient with normal pulmonary function and no comorbidities with 3-cm RUL cancer	26.08% 103	38.23% 151	15.19% 60	18.73% 74	1.77% 7	395	3.68
3*	75-year-old patient with normal pulmonary function, PS 1, central cancer candidate for right pneumonectomy	16.20% 64	13.16% 52	24.30% 96	28.61% 113	17.72% 70	395	2.82
4*	70-year-old patient with single station N2 disease and right upper lobe cancer	9.27% 37	15.29% 61	32.33% 129	27.57% 110	15.54% 62	399	2.75
5°	80-year-old patient with slowly growing partly solid T1aN0 peripheral lung cancer	4.55% 18	5.05% 20	11.11% 44	19.44% 77	59.85% 237	396	1.75
							OCHETY OF	THORACLOOMCO

Figure 4: Distribution of the answers in prioritizing clinical scenarios (related to question 8). (A) Clustered columns of each preference choose by every participant. (B) Double-entry table with the number of answers and their ranking order according to the percentage of each answer compared to the total responses (azure column) and overall score. RUL: right upper lobe.

Fifty-six percent of participants agreed with the reorganization of services. Only a minority of respondents (28.0%) felt forced to agree due to a lack of resources, but the answers from those at hospitals treating fewer patients who tested positive for COVID-19 were generally more positive (Fig. 6B).

Question 18: Are you and/or your thoracic surgery colleagues involved in the daily care of COVID-19 positive patients? (Answer rate 399/409, 97.5%) (Fig. 2)

The majority of respondents (63%) were involved in the daily care of patients with positive test results for COVID-19; surgeons in hospitals treating more patients with test results positive for COVID-19 were clearly more involved (Fig. 6C).

Surgery

Question 19: What kind of personal protective equipment (PPE) measures are taken during a COVID-19 negative thoracic surgical procedure? (Answer rate 399/409, 97.5%) (Fig. 2)

A total of 41% of respondents reported that all staff in the operating room used only standard equipment whereas the other respondents used filtering facepiece mask, aerosol filtration type 2 masks and other PPE measures.

Question 20: What kind of PPE measures are taken during a COVID-19 positive thoracic surgical procedure? (Answer rate 395/409, 96.5%) (Fig. 2)

Over half of the respondents (53%) used full PPE.

Postoperative care

Question 21: How is intensive care/postanaesthesia care availability for thoracic surgery patient affected by the COVID-19 pandemic situation? (Answer rate 377/409, 92.1%) (Fig. 2)

A total of 36% of respondents indicated no issue with intensity therapy unit bed numbers. The remaining respondents experienced reduced critical care capacity.

Question 22: Does chest drain management for your thoracic surgery patients during this COVID-19 pandemic differ from your standard management? (Answer rate 397/409, 97%) (Fig. 2)

The majority of participants (81%) stated they used the same system and the same chest drain protocol.

Question 23: Do discharge criteria for your thoracic surgery patients during this COVID-19 pandemic differ from your standard criteria? (Answer rate 398/409, 97.3%) (Fig. 2)

The majority of the respondents (59%) did not alter postoperative protocols. However, 30% tended to discharge patients earlier than usual (mostly because of bed capacity and concerns of COVID-19 infection).

Follow-up

Question 24: How is your postoperative contact with the patient influenced by the COVID-19 pandemic situation? (Answer rate 398/409, 97.3%) (Fig. 2)

One in 10 respondents switched to tele- or video consultations only. The other respondents were still seeing some patients in person.

Personal situation

Question 25: Anyone of your Department were tested positive to COVID-19? (Answer rate 399/409, 97.5%) (Fig. 2)

Almost half of the respondents had a team member who had contracted COVID-19 infection (32% were physicians/surgeons). Supplementary Material, Table S1 displays the proportion of COVID-19-positive personnel in thoracic surgery units from countries with more than 10 respondents in relation to the respective WHO COVID-19 lockdown day at the time of the survey.

Question 26: How do you feel as a thoracic surgeon during this pandemic? (Answer rate 399/409, 97.5%) (Fig. 2)

The majority of respondents (54%) felt unable to offer the best care for their patients.

Future thoughts (answer rate 86/409, 21%)

We received 86 comments. A total of 52% were remarks or questions on the current health care situation; 20% expressed hopeful sentiments; and 19% expressed fear or worries for the future (Supplementary Material, Table S2).

DISCUSSION

This survey explored the current practice among thoracic surgeons practicing during the COVID-19 pandemic during the second week of April 2020. The response rate of 23% was especially high, considering that only 1 response per institution was requested. This result may reflect the need among surgeons for more information and guidance about working through the pandemic. Indeed, another recent survey reflected a significant level of concern among health care workers regarding COVID-19 [6].

The ESTS is a European society, but more than one-fifth of the responses came from outside Europe, meaning this survey offers a global perspective. The survey also captured a wide demographic. Although the majority of respondents were from academic institutions, there was a wide range in the numbers of COVID-positive patients being managed. Overall, almost 90% of hospitals were postponing operations and had less critical care capacity, meaning almost all respondents were impacted in one way or another [7].

Screening of thoracic surgical patients was mainly conducted with a nasopharyngeal swab and was complemented by CT scanning in one-third of the cases. Single-swab testing might be considered a concern because the false negative rate in symptomatic patients is \sim 20% but can rise to 100% in asymptomatic patients [8]. There was also a wide variety in levels of testing. This result, of course, may reflect national governmental policy and is largely dependent on the test capacity per country/region (ranging from 453 to 32 414 tests per million inhabitants for countries represented in this survey) [9]. Surgery for patients whose test results were positive for the virus would almost always be postponed for at least 2 weeks, which is based on viral load modelling [10].

Although surgeons continue to see patients in person, there has been a significant shift to other forms of remote consultation. This approach is a big decision for most surgeons to make. It means that the basics of clinical assessment can be lost—including the ability to assess the patient, to undertake exercise testing and to build rapport. However, this situation is not unique to thoracic surgery: a survey among maxillofacial surgeons revealed similar practices [11].

THORACIC

7



B Are multidisciplinary decisions influenced by the COVID-19 pandemic situation?



Figure 5: Organization of preoperative workup stratified by impact per hospital. (A) Oncological workup. (B) Preoperative functional tests. COVID-19: coronavirus disease 2019; CPET: cardiopulmonary exercise testing; DLCO: diffusing capacity of the lung for carbon monoxide; EBUS: endobronchial ultrasound bronchoscopy; ECG: electrocardiography; PET-CT: positron emission tomography-computed tomography; V/Q: ventilation/perfusion.





Figure 6: Planning. (A) How is surgical planning affected by the coronavirus disease 2019 pandemic? (B) How do you feel about the affected planning? (C) Are you and/or your colleagues involved in daily care of coronavirus disease 2019-positive patients? ICU: intensive care unit; IMC: intermediate care; OR: operating room.

9

The preoperative component of thoracic oncology surgery has demonstrated resilience through the pandemic. Most hospitals preoperative assessment processes were not impacted or had to make minor changes. Although hospitals treating more patients who had test results positive for SARS-CoV-2 (the virus that causes COVID-19) were more limited. In accordance with current European Society for Medical Oncology guidelines, accurate staging continued to have a high priority although there was no mention of functional assessment [12]. There was evidence that the multidisciplinary meetings have adapted to the pandemic. Although there is no formal consensus on prioritizing surgical patients, a remarkable concordance in practice has emerged. Patients with low-grade cancer should be deferred when surgical capacity is lacking. Additionally, small localized malignant lesions have been considered for stereotactic radiotherapy. This practice is followed because it is perceived to entail a lower risk of severe respiratory complications and reduced utilization of critical care resources. Locally advanced N2 disease, with a poor prognosis, is not considered a priority. Other treatment options (including neoadjuvant treatment, which would allow deferring surgery until after the crisis, or definitive chemoradiation) could be utilized in these patients. Conversely, locally advanced N1 disease was perceived as a high surgical priority.

In reality, trying to prioritize a list of surgical patients, with constrained resources, can be extremely difficult because most organizations only provide COVID-19 recommendations with general principles categorized as high, medium and low priority [12-14]. Given that this system provides little differentiation between lung cancer patients being considered for surgery, daily practice remains difficult despite these recommendations.

Most surgeons feel that the risk of surgery during the current COVID-19 pandemic is higher, although many are clear that they do not know the exact magnitude of the added risk. Indeed, there is currently a lack of information in the literature regarding the perioperative course of patients who have test results positive for COVID-19, but an early report seems to confirm increased risk during this period [15].

It may therefore be considered alarming that 15% of participants are telling their patients 'not to worry' when they are being asked to give consent for surgery. Good surgical practice dictates that patients should be fully informed regarding surgical risk.

The perioperative surgical period was impacted to a much greater extent. This outcome is understandable when two-thirds of respondents were involved in the daily care of COVID-19 positive patients and even more in hospitals treating a large number of COVID-19 positive patients. Half of the respondents did not have access to full PPE when caring for these patients. These results are in line with the results of a survey of the Royal College of Surgeons where 57% of the responders described shortages of PPE [16]. PPE is clearly important for keeping health care professionals safe and well. Inadequate PPE was found to be a risk factor for COVID-19 infection among orthopaedic surgeons in Wuhan [17]. Given the fact that thoracic surgeons are exposed to aerosol-generating procedures, the risk may be much greater [18]. This observation, combined with the paucity of testing, means that health care workers continue to work with a sense of significant personal threat.

Postoperative care might be considered against the small numbers of patients proceeding with surgery. However, a potentially significant finding is that 4 of 5 respondents have not adapted the management of chest drains, despite the fact that some societies recommend the use of a digital or a closed filter system [19]. There is a reasonable concern that aerosol production by an air leak could spread the viral load, but evidence on this topic is lacking [20].

With clear changes in the surgical journey, it can be appreciated why 54.4% of responders were concerned they were unable to provide the best care for their patients and were worried about their own emotional health. Indeed stress-related symptoms are being regularly reported in frontline health care workers during the COVID-19 pandemic [21, 22].

Limitations

This survey has some limitations. The questions are related only to the practice of thoracic oncology surgery. The effect of the pandemic on other thoracic surgical patients remains relevant and fully warrants further investigation. Because responses will also ultimately change as the pandemic progresses [23], we plan to take a second survey at a later date to gain further data. The fact that some respondents felt there was no answer that accurately described their specific situation should be considered when interpreting the overall results of this survey. Finally, the representativeness of this survey should be carefully considered when interpreting the results. The majority of the respondents' hospitals were treating large numbers of patients with COVID-19 at the time of the survey. This situation may not represent the situation present in hospitals less affected by the pandemic.

CONCLUSION

In conclusion, this survey provides evidence that the practice of thoracic oncological surgery has been severely impacted globally. It illustrates important factors such as protection for health care workers and changes to the standard management of patients with lung cancer. The results also suggest a lack of consensus among thoracic surgeons related to the treatment of patients as the pandemic progresses.

To ensure that the quality of care provided for patients remains high, we suggest that there is an urgent need for guidelines that adjust for pressures on services and resources and also for the risk of perioperative infection. In addition to oncology surgery, there is a need to investigate how other aspects of thoracic surgery practice may have been impacted, including the areas of trauma, benign elective work and the management of acute and infective work.

SUPPLEMENTARY MATERIAL

Supplementary material is available at EJCTS online.

ACKNOWLEDGEMENTS

The authors would like to thank all members of the ESTS learning affairs committee who helped in refining the questionnaire. The authors would also like to thank all participating thoracic surgeons for completing the survey at a difficult time. Conflict of interest: none declared.

Author contributions

Lieven P. Depypere: Conceptualization; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing-original draft; Writing-review & editing. Niccolò Daddi: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Resources; Software; Supervision; Validation; Visualization; Writing-original draft; Writing-review & editing. Michael R. Gooseman: Writing-original draft; Writing-review & editing. Michael R. Gooseman: Writing-review & editing. Hasan F. Batirel: Conceptualization; Formal analysis; Funding acquisition; Investigation; Writing-original draft; Writing-review & editing. Alessandro Brunelli: Conceptualization; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing-original draft; Writing-review & editing.

Reviewer information

European Journal of Cardio-Thoracic Surgery thanks Kieren G. Mcmanus, Thomas F. Molnar and Jeffrey L. Port and the other, anonymous reviewer(s) for their contribution to the peer review process of this article.

REFERENCES

- [1] https://www.who.int/news-room/detail/08-04-2020-who-timeline---covid-19.
- Global Covid-19 Case Fatality Rates. CEBM. https://www.cebm.net/glo bal-covid-19-case-fatality-rates/ (24 April 2020, date last accessed).
- [3] Oksanen A, Kaakinen M, Latikka R, Savolainen I, Savela N, Koivula A. Regulation and trust: COVID-19 mortality in 25 European countries. JMIR Public Health Surveill 2020;6:e19218.
- [4] Verelst F, Kuylen E, Beutels P. Indications for healthcare surge capacity in European countries facing an exponential increase in coronavirus disease (COVID-19) cases, March 2020. Euro Surveill 2020;25: 2000323.
- [5] Einav S, Hick JL, Hanfling D, Erstad BL, Toner ES, Branson RD *et al.* Surge capacity logistics: care of the critically ill and injured during pandemics and disasters: CHEST consensus statement. Chest 2014;146:e175.
- [6] https://m3globalresearch.blog/2020/03/07/coronavirus-week-1/.
- [7] Litton E, Bucci T, Chavan S, Ho YY, Holley A, Howard G et al. Surge capacity of intensive care units in case of acute increase in demand caused by COVID-19 in Australia. Med J Aust 2020;212:463–7.

- [8] https://www.worldometers.info/coronavirus/ (26 April 2020, date last accessed).
- [9] Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reactionbased SARS-CoV-2 tests by time since exposure. Ann Intern Med 2020; doi:10.7326/M20-1495.
- [10] Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM *et al.* Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020;20:656–7.
- [11] Maffia F, Fontanari M, Vellone V, Cascone P, Mercuri LG. Impact of COVID-19 on maxillofacial surgery practice: a worldwide survey. Int J Oral Maxillofac Surg 2020;49:827-35.
- [12] https://www.esmo.org/guidelines/cancer-patient-management-duringthe-covid-19-pandemic/lung-cancer-in-the-covid-19-era.
- [13] https://www.brit-thoracic.org.uk/about-us/covid-19-information-forthe-respiratory-community/.
- [14] Thoracic Surgery Outcomes Research Network, Inc. COVID-19 guidance for triage of operations for thoracic malignancies: a consensus statement from Thoracic Surgery Outcomes Research Network. Ann Thorac Surg 2020;110:692–6.
- [15] Peng S, Huang L, Zhao B, Zhou S, Braithwaite I, Zhang N et al. Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis. J Thorac Cardiovasc Surg 2020;160: 585–92.e2.
- [16] Rimmer A. Covid-19: third of surgeons do not have adequate PPE, royal college warns. BMJ 2020;369:m1492.
- [17] Guo X, Wang J, Hu D, Wu L, Gu L, Wang Y, et al. Survey of COVID-19 disease among orthopaedic surgeons in Wuhan, People's Republic of China. J Bone Joint Surg 2020;102:847–54.
- [18] Zucco L, Levy N, Ketchandji D, Aziz M, Ramachandran SK. Perioperative Considerations for the 2019 Novel Coronavirus (COVID-19). 2020. https://www.apsf.org/news-updates/perioperative-considerations-forthe-2019-novel-coronavirus-covid-19/ (12 February 2020, date last accessed).
- [19] Hallifax R, Wrightson JM, Bibby A, Walker S, Stanton A, Fonseka DD. Pleural Services during the COVID-19 Pandemic (V2.0). British Thoracic Society, 2020.
- [20] Bilkhu R, Viviano A, Saftic I, Billè A (2020). COVID-19: Chest Drains with Air Leak–The Silent 'Super Spreader'? CTSNet, Inc. Dataset. https://doi. org/10.25373/ctsnet.12089130.v1.
- [21] Lai J, Ma S, Wang Y, Cai Z, Hu J, Wei N et al. Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA Netw Open 2020;3:e203976.
- [22] Kisely S, Warren N, McMahon L, Dalais C, Henry I, Siskind D. Occurrence, prevention, and management of the psychological effects of emerging virus outbreaks on healthcare workers: rapid review and meta-analysis. BMJ 2020;369:m1642.
- [23] Zagury-Orly I, Schwartzstein RM. Covid-19-a reminder to reason. N Engl J Med 2020;383:e12.